scholarly journals Prognostic impact of primary tumor location on survival in metastatic colorectal cancer patients: A single center experience

2019 ◽  
pp. 1 ◽  
Author(s):  
Tarik Demir ◽  
Murat Araz ◽  
Ezgi Coban ◽  
Altay Aliyev ◽  
Mesut Seker ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Tumor Location ◽  
Prognostic Impact ◽  
Single Center ◽  
Primary Tumor Location ◽  
Single Center Experience ◽  
Colorectal Cancer Patients

Primary tumor location and bevacizumab effectiveness in metastatic colorectal cancer patients.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 3593-3593
Author(s):  
Wen-zhuo He ◽  
Chang Jiang ◽  
Fang-xin Liao ◽  
Qiong Yang ◽  
Peng-fei Kong ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Tumor Location ◽  
Primary Tumor Location ◽  
Colorectal Cancer Patients

scholarly journals The effect of the primary tumor location on the survival of colorectal cancer patients after radical surgery

2018 ◽  
Vol 15 (14) ◽  
pp. 1640-1647
Author(s):  
Xiaona Cai ◽  
Dianna Gu ◽  
Mengfeng Chen ◽  
Linger Liu ◽  
Didi Chen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Radical Surgery ◽  
Tumor Location ◽  
Primary Tumor Location ◽  
Colorectal Cancer Patients

scholarly journals Plasma protein expression differs between colorectal cancer patients depending on primary tumor location

2020 ◽  
Vol 9 (14) ◽  
pp. 5221-5234
Author(s):  
Matilda Holm ◽  
Sakari Joenväärä ◽  
Mayank Saraswat ◽  
Tiialotta Tohmola ◽  
Ari Ristimäki ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Protein Expression ◽  
Cancer Patients ◽  
Plasma Protein ◽  
Primary Tumor ◽  
Tumor Location ◽  
Primary Tumor Location ◽  
Colorectal Cancer Patients

scholarly journals Prognostic impact of primary tumor location in metastatic colorectal cancer (mCRC). A 5 year retrospective analysis of our treated population.

2017 ◽  
Vol 28 ◽  
pp. iii118-iii119
Author(s):  
Gonçalo Atalaia ◽  
Marta Vaz Baptista ◽  
Tiago Tomás ◽  
Susana Almeida ◽  
Inês Eiriz ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Retrospective Analysis ◽  
Primary Tumor ◽  
Tumor Location ◽  
Prognostic Impact ◽  
Primary Tumor Location

Primary tumor location impacts survival in colorectal cancer patients after resection of liver metastases

2020 ◽  
Vol 122 (4) ◽  
pp. 745-752
Author(s):  
Katherine Bingmer ◽  
Asya Ofshteyn ◽  
Jonathan T. Bliggenstorfer ◽  
William Kethman ◽  
John B. Ammori ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Tumor Location ◽  
Primary Tumor Location ◽  
Colorectal Cancer Patients

Bevacizumab effectiveness and primary tumor location in metastatic colorectal cancer patients.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 683-683 ◽  
Author(s):  
Wen-zhuo He ◽  
Qiong Yang ◽  
Chang Jiang ◽  
Fang-xin Liao ◽  
Shou-sheng Liu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Colon Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Tumor Location ◽  
First Line ◽  
Primary Tumor Location ◽  
Colon Cancers

683 Background: There is currently no consensus about whether bevacizumab effectiveness is associated with the primary tumor location of metastatic colorectal cancer (mCRC). The aim of this study was to assess whether the primary tumor location was a predictor for bevacizumab treatment. Methods: From 2004 to 2013, 740 patients with mCRC treated with oxaliplatin / 5-FU / leucovorin (mFOLFOX6) or irinotecan / 5-FU / leucovorin (FOLFIRI) (CT group) and 244 patients treated with bevacizumab plus mFOLFOX6 or FOLFIRI (CT + B group) as first-line setting were included from Sun yat-sen university cancer center. Right-side colon cancers included those occurring in the cecum, ascending colon or transverse colon. Left-side colon cancers included those from descending or sigmoid colon. The primary outcome was overall survival (OS). Kaplan-Meier curves with log-rank tests were used to detect difference. All statistical tests were two sided. Results: 222 right-side colon, 259 left-side colon and 259 rectal cancer patients were included in CT group while 78 right-side colon, 86 left-side colon and 80 rectal cancer patients were included in CT + B group. Patients in CT + B group had similar OS compare with CT group only when the primary tumor located at right-side colon (median OS was 19.6 months for CT + B group versus 19.5 months for CT group, P = 0.269). For left-side colon cancer, significantly longer OS were observed in CT + B than CT group (22.3 months versus 21.9 months, P = 0.014). For rectal cancer patients, those in CT + B group also had longer OS than CT group (25.9 months versus 21.1 months, P = 0.005). Conclusions: Our data suggested that patients with right-side colon cancer could not get survival benefit from the addition of bevacizumab to first-line chemotherapy. Further data from randomized trials are needed to test our hypothesis. [Table: see text]

scholarly journals The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival

2019 ◽  
Vol 27 (5) ◽  
pp. 1580-1588 ◽  
Author(s):  
Nelleke P. M. Brouwer ◽  
Dave E. W. van der Kruijssen ◽  
Niek Hugen ◽  
Ignace H. J. T. de Hingh ◽  
Iris D. Nagtegaal ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Relative Survival ◽  
Tumor Location ◽  
Primary Tumor Location ◽  
Metastatic Sites ◽  
The Impact

Abstract Purpose We explored differences in survival between primary tumor locations, hereby focusing on the role of metastatic sites in synchronous metastatic colorectal cancer (mCRC). Methods Data for patients diagnosed with synchronous mCRC between 1989 and 2014 were retrieved from the Netherlands Cancer registry. Relative survival and relative excess risks (RER) were analyzed by primary tumor location (right colon (RCC), left colon (LCC), and rectum). Metastatic sites were reported per primary tumor location. Survival was analyzed for metastatic sites combined and for single metastatic sites. Results In total, 36,297 patients were included in this study. Metastatic sites differed significantly between primary tumor locations, with liver-only metastases in 43%, 54%, and 52% of RCC, LCC, and rectal cancer patients respectively (p < 0.001). Peritoneal metastases were most prevalent in RCC patients (33%), and lung metastases were most prevalent in rectal cancer patients (28%). Regardless of the location of metastases, patients with RCC had a worse survival compared with LCC (RER 0.81, 95% CI 0.78–0.83) and rectal cancer (RER 0.73, 95% CI 0.71–0.76). The survival disadvantage for RCC remained present, even in cases with metastasectomy for liver-only disease (LCC: RER 0.66, 95% CI 0.57–0.76; rectal cancer: RER 0.84, 95% CI 0.66–1.06). Conclusions This study showed significant differences in relative survival between primary tumor locations in synchronous mCRC, which can only be partially explained by distinct metastatic sites. Our findings support the concept that RCC, LCC and rectal cancer should be considered distinct entities in synchronous mCRC.

Sign in / Sign up

Export Citation Format

Share Document